References
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
- Miller VM, Black DM, Brinton EA, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009;2:228–39
- Hodis HN, Mack WJ. A ‘window of opportunity’: the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res 2010 Oct 25. Epub ahead of print
- Salpeter SR, Walsh JM, Greyber E., Ormiston TM, Salpeter EE. Mortality associated with HRT in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791–804
- Panay N, Ylikorkala O, Archer DF, Rakov V, Gut R, Lang E. Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. Climacteric 2007;10:120–31
- Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, BerrinoF, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26: 1260–8
- Canonico M, Oger E, Plu-Bureau G, et al. Estrogen and Thromboembolism Risk (ESTHER) Study Group. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115: 840–5
- Panay N, Fenton A. Bioidentical hormones: what is all the hype about? Climacteric 2010;13:1–3
- Pinkerton JV, Utian WH, Constantine GD, Olivier S, PickarJH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16: 1116–24